63 reports of this reaction
1.3% of all MECLIZINE HCL reports
#20 most reported adverse reaction
VERTIGO is the #20 most commonly reported adverse reaction for MECLIZINE HCL, manufactured by Rising Pharma Holdings, Inc.. There are 63 FDA adverse event reports linking MECLIZINE HCL to VERTIGO. This represents approximately 1.3% of all 4,811 adverse event reports for this drug.
Patients taking MECLIZINE HCL who experience vertigo should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VERTIGO is a less commonly reported adverse event for MECLIZINE HCL, but still significant enough to appear in the safety profile.
In addition to vertigo, the following adverse reactions have been reported for MECLIZINE HCL:
The following drugs have also been linked to vertigo in FDA adverse event reports:
VERTIGO has been reported as an adverse event in 63 FDA reports for MECLIZINE HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
VERTIGO accounts for approximately 1.3% of all adverse event reports for MECLIZINE HCL, making it a notable side effect.
If you experience vertigo while taking MECLIZINE HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.